GWRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Guidewire Software Inc (GWRE) is not a strong buy for a beginner, long-term investor at the moment. While the company has shown strong revenue growth and is well-positioned in the AI-driven software space, the technical indicators are bearish, insider selling has surged significantly, and the financial performance shows a steep decline in net income and EPS. The options data also indicates a cautious sentiment, with a relatively low Open Interest Put-Call Ratio of 0.43 and Option Volume Put-Call Ratio of 0.7. Given the investor's preference for long-term investments and the lack of immediate positive trading signals, it is better to hold off on buying this stock for now.
The technical indicators for GWRE suggest a bearish trend. The MACD histogram is negative and expanding, RSI is neutral at 38.298, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 156.218, with support at 148.651 and resistance at 163.786.
Revenue increased by 24.05% YoY in Q2
Guidewire's partnership with MyChoice through the Insurtech Vanguards program enhances its position in the insurance technology space.
Analysts highlight the company's strong positioning in AI and defensive nature in the software sector.
Net income dropped by -261.25% YoY, and EPS fell by -255.56% YoY in Q2
Insider selling has increased by 522.34% in the last month.
Bearish technical indicators and a lack of immediate trading signals.
Analysts have lowered price targets due to software multiple contraction and AI disruption overhang.
In Q2 2026, Guidewire's revenue grew by 24.05% YoY to $359.1M, but net income dropped significantly by -261.25% YoY to $60.1M, and EPS fell by -255.56% YoY to 0.7. Gross margin improved to 64.47%, up 4.17% YoY.
Analysts maintain a generally positive outlook on GWRE, with multiple Buy and Outperform ratings. However, most firms have lowered their price targets, citing software multiple contraction and AI-related risks. Current price targets range from $175 to $250, with a neutral rating from Citi at $178.
